<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884048</url>
  </required_header>
  <id_info>
    <org_study_id>CentralHNF BTI-RADSM</org_study_id>
    <nct_id>NCT04884048</nct_id>
  </id_info>
  <brief_title>Multicentric Bone Tumor Imaging Report and Data System</brief_title>
  <acronym>BTI-RADS M</acronym>
  <official_title>Multicentric Study for the Validation and Improvement of a Structured Report Tool for the Imaging Characterization of Bone Tumors - Bone Tumor Imaging Report and Data System (BTI-RADS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupement des Hopitaux de l'institut catholique de Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Cochin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hopital Jules Courmont - Centre Hospitalier Lyon Sud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Purpan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study a previously described structured multimodality image report system for the&#xD;
      characterization of focal bone lesions is evaluated in a larger patient population. The&#xD;
      objective of this study is to evaluate the performance of this tool stratifying the&#xD;
      malignancy risk of bone tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The characterization of focal bone lesions by imaging can be difficult. Primary bone sarcomas&#xD;
      are rare, accounting for 0.2% of all malignant tumors occurring at an estimated rate of one&#xD;
      tenth that of soft tissue sarcomas. Focal bone lesions have a wide differential diagnosis,&#xD;
      including benign and malignant neoplasms, metabolic disorders, degenerative changes, and&#xD;
      tumor-like conditions. The precise differentiation between benign and malignant bone tumors&#xD;
      is essential for optimal patient management, with a considerable impact on prognosis and&#xD;
      survival rates. The relapse-free survival of patients with sarcoma is significantly better&#xD;
      when treatment is guided by a multidisciplinary oncology committee. In addition, surgical&#xD;
      treatment in referral centers reduces the risk of recurrence and death.&#xD;
&#xD;
      Due to the rarity of primary malignant bone neoplasms and the varied imaging presentation of&#xD;
      focal bone lesions, radiologists outside of cancer centers tend to have little experience&#xD;
      with this type of abnormality. Thus, imaging reports can be unclear and misleading,&#xD;
      increasing the risk of misdiagnosis and suboptimal patient management. Previous studies have&#xD;
      largely addressed the specific imaging features of bone tumors, and a systematic approach to&#xD;
      the assessment of bone tumors has been recommended. However, there is little information on&#xD;
      how to combine these imaging results and which are most relevant for characterization of&#xD;
      lesions.&#xD;
&#xD;
      Various studies have demonstrated the value of structured analysis of medical information in&#xD;
      clinical decision making and such an approach is currently used for the assessment of&#xD;
      malignancy in various organs and systems. For bone tumors, this approach requires the&#xD;
      combined analysis of several demographic, clinical and imaging characteristics. Of the large&#xD;
      number of features described, 16 (seven benign and nine malignant) were considered relevant&#xD;
      for the differentiation between benign and malignant tumors. Three signs (Lodwick-Madewell&#xD;
      grade III, aggressive periosteal reaction and suspected or confirmed metastatic disease) had&#xD;
      a mean frequency of associated malignancy greater than 80%. Thus, lesions showing any of&#xD;
      these signs should be considered malignant until proven otherwise. It should be noted that&#xD;
      these 3 signs are CT or standard radiography criteria, confirming the essential role of&#xD;
      X-ray-based methods for the characterization of bone tumors. On the contrary, certain signs&#xD;
      classically suggestive of malignancy, such as a history of pain, pathological fracture and&#xD;
      endosteal scalloping, have been identified as non-determining indicators for the&#xD;
      characterization of these lesions. These data could contribute to a more precise assessment&#xD;
      of the aggressive potential of a bone tumor. Finally, on the basis of these results, an&#xD;
      evidence-based classification of solitary bone lesions (BTI-RADS) was proposed, allowing the&#xD;
      stratification of bone tumors into four classes with an average frequency of malignancy of&#xD;
      0%; 2.2% (1.1 - 3.1%), 20.1% (17 - 24.4%) and 71% (65.6 - 75%) for each class. This system&#xD;
      was applicable for readers with different levels of expertise, including a general&#xD;
      radiologist, with acceptable interobserver reproducibility (Kappa = 0.67). BTI-RADS could be&#xD;
      particularly beneficial outside of specialized oncology centers.&#xD;
&#xD;
      However, the BTI-RADS was established based on a single-center analysis of a relatively small&#xD;
      patient population. The application of this system in a larger population in multicentric&#xD;
      study is necessary to validate this tool and potentially refine it through the identification&#xD;
      of additional pertinent criteria for lesion characterization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Structured report item analysis</measure>
    <time_frame>30 minutes</time_frame>
    <description>Each component of the structure report system will be analyzed and compared between the study groups.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Bone Neoplasm</condition>
  <arm_group>
    <arm_group_label>Benign bone tumors</arm_group_label>
    <description>Patients with benign lesions confirmed either by histology or imaging follow-up showing lesion stability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Malignant bone tumors</arm_group_label>
    <description>Patients with malignant lesions confirmed by histology.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Radiographs</intervention_name>
    <description>Analysis of the images acquired for the initial characterization of bone lesions using a systematic report system</description>
    <arm_group_label>Benign bone tumors</arm_group_label>
    <arm_group_label>Malignant bone tumors</arm_group_label>
    <other_name>CT</other_name>
    <other_name>MRI</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred for the initial imaging characterization of focal bone lesions.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient evaluated for the initial imaging characterization of a focal bone lesion.&#xD;
&#xD;
          -  Availability of conventional radiographs or a CT study for patients with lesions in&#xD;
             the spine, pelvis or calvarium.&#xD;
&#xD;
          -  Availability of a contrast enhanced MRI study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prio surgery&#xD;
&#xD;
          -  History of neoadjuvant threatment&#xD;
&#xD;
          -  Contra-indications to contrast enhanced MRI&#xD;
&#xD;
          -  Diffuse bone pathology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pedro Teixeira, Prof</last_name>
    <phone>33 3 83 85 21 61</phone>
    <email>p.teixeira@chru-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alain Blum, Prof</last_name>
    <phone>33 3 83 85 21 61</phone>
    <email>alain.blum@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospital of Nancy</name>
      <address>
        <city>Nancy</city>
        <state>Grand-Est</state>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Teixeira, Prof</last_name>
      <phone>33 3 83 85 21 61</phone>
      <email>p.teixeira@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Paris Centre site Cochin APHP</name>
      <address>
        <city>Paris</city>
        <state>Ille De France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fadila MIHOUBI-BOUVIER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariem BEN HAJ AMOR, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupement des Hopitaux de l'institut catholique de Lille</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine MALRAIT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sammy BADR, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastien Aubry, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire FOURNIER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Université Lyon 1 - Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jean-Baptiste Pialat, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de Purpan - CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hubert BASSELERIE, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Ribeiro GJ, Gillet R, Hossu G, Trinh JM, Euxibie E, Sirveaux F, Blum A, Teixeira PAG. Solitary bone tumor imaging reporting and data system (BTI-RADS): initial assessment of a systematic imaging evaluation and comprehensive reporting method. Eur Radiol. 2021 Oct;31(10):7637-7652. doi: 10.1007/s00330-021-07745-9. Epub 2021 Mar 25.</citation>
    <PMID>33765161</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Pedro TEIXEIRA-GONDIM, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Bone Neoplasms</keyword>
  <keyword>Multidetector Computed Tomography</keyword>
  <keyword>Radiographs</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Evidence-Based Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

